“Is There a New Non-Opioid Pain Medication After Joint Replacement? What Patients Should Know About Journavx (Suzetrigine)”
Pain control is one of the biggest concerns patients have before hip or knee replacement surgery. Most patients want strong pain relief, but many also want to avoid unnecessary opioid exposure, sedation, constipation, nausea, or the worry that can come with opioid medications.
A newer medication called Journavx, also known by its generic name suzetrigine, has brought attention to a different way of treating acute pain. It is not an opioid. It is not a magic solution. But it may become an important tool within a broader recovery plan designed to help patients move earlier, participate in therapy, and recover with greater confidence.
The goal is not simply to get through surgery. The goal is to RESTORE your mobility to REGAIN your life.
What Is Journavx?
Journavx is the brand name for suzetrigine, an oral prescription medication approved by the U.S. Food and Drug Administration for the treatment of moderate-to-severe acute pain in adults. Acute pain is short-term pain, often related to surgery, injury, or another temporary cause.
Its approval is notable because it represents a new class of non-opioid pain medicine. Rather than working like an opioid, Journavx targets pain-signaling pathways in the peripheral nervous system before pain signals travel centrally to the brain.
That distinction matters. For many years, patients and physicians have had to balance the benefits of opioids for surgical pain against their side effects and risks. A non-opioid option gives clinicians another potential tool, particularly when used as part of a thoughtful multimodal pain plan.
How Is Journavx Different From an Opioid?
Opioid medications work primarily through opioid receptors in the brain, spinal cord, and other parts of the body. They can be effective for acute surgical pain, but they may also cause side effects such as sleepiness, nausea, constipation, confusion, breathing concerns, and dependence in some patients.
Journavx works differently. It blocks a sodium channel involved in transmitting pain signals from the peripheral nerves. In simpler terms, it aims to reduce pain signaling closer to where pain starts, rather than relying on opioid effects in the central nervous system.
This does not mean that Journavx is automatically better for every patient or every operation. It means it is different, and that difference may be useful when the goal is effective pain control with less reliance on opioids.
Does This Mean Patients Will Not Need Opioids?
Not necessarily. Pain after hip or knee replacement is real, and every patient responds differently. Some patients may still need a small amount of opioid medication for breakthrough pain, especially early after surgery.
The better question is not whether one medication can replace everything else. The better question is how to build a pain plan that uses the right medications, at the right time, for the right patient.
For many patients, the safest and most effective approach is multimodal pain management. That means using several complementary strategies together, rather than relying heavily on any single medication.
What Is Multimodal Pain Management?
Multimodal pain management is a modern approach to surgical recovery. It combines different treatments that work through different pathways, with the goal of improving comfort while reducing side effects.
After joint replacement, this may include regional anesthesia, anti-inflammatory medications when appropriate, acetaminophen, ice, elevation, compression, physical therapy, early walking, and selective use of other medications. In some patients, a medication such as Journavx may become one additional part of this broader plan.
This approach matters because pain control is not just about comfort. Better pain control can help patients walk earlier, participate in therapy, sleep better, and regain confidence during recovery.
Could Journavx Be Used After Knee or Hip Replacement?
Journavx is approved for moderate-to-severe acute pain in adults, including postoperative pain. However, the major clinical trials supporting approval were performed in specific acute surgical pain models, including abdominoplasty and bunionectomy. Those studies showed superior pain reduction compared with placebo, but they were not designed specifically around total hip or total knee replacement.
That distinction is important. Hip and knee replacement patients have unique recovery needs, including early walking, therapy, swelling control, motion goals, and careful coordination with other medications.
For appropriate patients, Journavx may be considered as part of an opioid-sparing postoperative pathway. But the decision should be individualized. A patient’s medical history, kidney and liver function, medication interactions, insurance coverage, surgical plan, and anesthesia protocol all matter.
What Are the Important Safety Considerations?
Like any prescription medication, Journavx is not appropriate for every patient. The prescribing information includes important considerations regarding dosing, liver impairment, drug interactions, and avoidance of grapefruit products during treatment.
The medication is intended for the shortest duration consistent with treatment goals, and clinical use for acute pain has not been studied beyond 14 days. Patients should not start, stop, or combine pain medications without guidance from their surgical team.
This is especially important after joint replacement, where patients may also be taking medications for blood clot prevention, inflammation, nausea, sleep, constipation, or other medical conditions.
What Should Patients Ask Their Surgeon?
If you are preparing for joint replacement and are interested in opioid-sparing pain control, it is reasonable to ask about your recovery plan before surgery. A few helpful questions include:
· Am I a candidate for an opioid-sparing pain pathway?
· What medications will I take after surgery, and why?
· How do we balance pain relief with safety and side effects?
· What should I do if my pain is not controlled at home?
· Could a newer non-opioid medication such as Journavx be appropriate for me?
These questions can help set expectations and create a plan before pain becomes a problem.
The Bottom Line
Journavx is a promising new non-opioid medication for acute pain. It represents an important step forward because it gives physicians another way to think about postoperative pain control.
At the same time, it should be viewed with thoughtful optimism rather than hype. It is not a stand-alone solution, and it does not replace the need for careful surgical technique, anesthesia planning, swelling control, early mobility, physical therapy, and individualized recovery guidance.
For patients undergoing hip or knee replacement, the future of pain control is likely not one medication. It is a coordinated pathway designed to control pain, reduce unnecessary opioid exposure, and support recovery.
At its core, the goal remains simple: RESTORE your mobility to REGAIN your life.
Medical Disclaimer:
This article is for general informational purposes only and does not constitute medical advice. Medication decisions should be made with your surgeon or healthcare team based on your individual medical history and recovery plan.
Selected References
1. U.S. Food and Drug Administration. FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain. FDA News Release. January 30, 2025.
2. JOURNAVX (suzetrigine) tablets, for oral use. Full Prescribing Information. Vertex Pharmaceuticals; Initial U.S. Approval: 2025.
3. Bertoch T, et al. Suzetrigine, a Nonopioid NaV1.8 Inhibitor for Treatment of Moderate-to-Severe Acute Pain: Two Phase 3 Randomized Clinical Trials. Anesthesiology. 2025.
4. Jones J, et al. Selective Inhibition of NaV1.8 with VX-548 for Acute Pain. New England Journal of Medicine. 2023.
5. Institute for Clinical and Economic Review. Suzetrigine for Acute Pain: Effectiveness and Value. Final Evidence Report. March 31, 2025.
Comments